The Errand That Rode in the Passenger Seat
November 2, 2026 — You remember the errand. You carry it with you. Somehow, it still doesn’t get done.
All Stories
The New Peptide Policy Is Narrower Than a “Green Light”
October 30, 2026 — An October 30 federal notice names six peptide substances for conditional compounding enforcement discretion. It does not approve those drugs or settle every access question.
Same Peptide, Different Supplier: Five Questions Beyond the Purity Claim
October 27, 2026 — Compare the batch records, testing scope and answers behind similar-looking research products.
Your Midlife Health Story May Still Have Another Chapter
October 27, 2026 — A British cohort offers hope about later health markers after midlife weight loss. Its findings deserve a careful reading, without promises of erased risk.
The Peptide Boom, From TikTok Bans to Hospitalizations: What This Week’s Headlines Really Mean
October 25, 2026 —
When the MRI Says “Normal” but Your Knee Still Feels Wrong
October 23, 2026 — A reassuring scan does not always resolve persistent knee symptoms. What that means for recovery—and what the limited human evidence can actually tell us about BPC-157.
A Peptide Just Carried Actinium-225 Into Phase 3. BMS Says It Met the Trial’s Main Goal.
October 23, 2026 — RYZ101 combines a tumor-seeking peptide with one of the most destructive radioactive payloads medicine can deploy. Bristol Myers Squibb’s first Phase 3 readout suggests the idea may have crossed an extraordinary thres…
ER-100 and Yamanaka Factors: The Bid to Restore Vision by Reprogramming Cells
October 23, 2026 — The experimental gene therapy borrows tools that can reset a cell’s identity. Its more delicate goal is to recover function without making the cell start over.
An Implant Stimulated a Nerve to Treat Rheumatoid Arthritis. The Sham Group Shows the Difference.
October 22, 2026 —
Creatine Raised a Kidney Blood Test. Two 2026 Reviews Ask What Actually Changed.
October 22, 2026 —
You’re Still Doing the Work. You’d Like Your Waist to Show It.
October 19, 2026 — Tesamorelin raises an intriguing question for men in midlife: could changing growth-hormone signaling change abdominal fat? A small human trial gives us a reason to look closer.
Tesamorelin and the New Race to Lose the Right Fat
October 19, 2026 — A fresh obesity-drug deal puts fat distribution and lean mass in the spotlight. Tesamorelin’s next clinical question goes further: can a change on a scan help people function better?
Why Are People With ADHD Talking About Weight-Loss Drugs?
October 18, 2026 — Some GLP-1 users say ordinary tasks feel easier. Their reports raise a bigger question about focus, mental noise, and the search for help beyond Adderall.
ADHD: You’re Capable of So Much. Why Is Getting Through the Day So Hard?
October 18, 2026 — The unanswered message. The task you can’t start. The search for a steadier day—and what Semax, Selank and GLP-1 research can actually tell you.
The Hidden Geometry of Mastery: What the Brain’s “11 Dimensions” Really Mean
October 16, 2026 — An eye-catching mathematical study of rat neurons offers a new way to think about skill. Human research adds evidence that practice changes brain networks, while intelligence and creativity may depend on how widely se…
A Collagen Dressing Closed More Difficult Diabetic Foot Wounds. The Trial’s Narrow Win Matters.
October 15, 2026 — In a 170-person randomized trial of difficult diabetic foot ulcers, 42% of wounds closed with a collagen-PHMB matrix plus standard care, versus 27% with standard care alone. The result has important limits.
A Senolytic Trial Improved Liver Scarring. Thirty-One Participants Are Enough to Ask the Next Question.
October 15, 2026 — An October 2026 randomized trial reported fibrosis improvement with dasatinib plus quercetin in MASH. The biopsy signal is promising but comes from a small trial.
An Antioxidant Helped Some Muscles Recover—and Delayed Repair in Others
October 15, 2026 — A 24-man randomized crossover study found NAC helped muscle repair in participants with low muscle glutathione but impaired repair in those with high muscle glutathione.
Your Immune System May Have Its Own Aging Trajectory. A New Cell Map Explains Why.
October 15, 2026 — An October 2026 Immunity study compares immune-cell patterns in 2,609 people. Learn why the granzyme K/B ratio is promising but not a clinical aging test.
KPV’s Most Interesting Story Is a Delivery Problem
October 14, 2026 — KPV can be cargo or part of a targeting system. Follow the transporter, hydrogel and nanoparticle research without mistaking mouse data for human benefit.
Cold Plunge or Hot Bath? Start With the Recovery You Actually Need
October 14, 2026 — Soreness, restored strength, tissue repair and muscle growth are different goals. Read hot- and cold-water recovery studies with that distinction in mind.
The Missing Chapter in GLP-1 Weight Loss: What Happens After Treatment Stops
October 14, 2026 — What happens when GLP-1 treatment ends? Compare withdrawal trials, exercise follow-up and the limits of evidence about keeping weight off.
Bonn’s Cell-Rejuvenation Study Has a Surprising Strength: It Takes Its Time
October 14, 2026 — Why Bonn’s slow blood-to-neural-stem-cell conversion may help aging research, and why a younger molecular clock is not proof of human rejuvenation.
Sleep Is Part of Your Muscle-Recovery Plan, Not Time Away From It
October 14, 2026 — Sleep-loss studies show changes in muscle protein synthesis, not instant muscle loss. Explore the exercise findings and practical limits of the evidence.
Can Creatine Help a Sleep-Deprived Brain? What the Small Trials Show.
October 14, 2026 — Small 2024 and 2026 trials report selected cognitive benefits during sleep loss. Review cutoffs, research doses and real-world limits explain the uncertainty.
An NAD+ Booster Doubled Blood NAD+. A Memory Benefit Was Not Demonstrated.
October 14, 2026 — A 12-week NR trial raised blood NAD+ but found no statistically significant cognitive benefit in older adults with amnestic mild cognitive impairment.
BPC-157 Won an FDA Advisory Vote. A New Review Found Only 30 Human Participants.
October 14, 2026 — A new BPC-157 review included 30 participants. Older human reports and a July advisory vote complicate the story; reliable efficacy remains unestablished.
An Experimental Cream Shifted a Skin-Aging Clock. What Actually Changed?
October 14, 2026 — Rubedo reports a lower skin-aging clock score in 11 paired samples after experimental RLS-1496 cream. Clinical rejuvenation remains unproven.
A Human Eye-Reprogramming Trial Has Its First Results. The Sample Size Is Three.
October 14, 2026 — Life Biosciences reports early tolerability in three ER-100 participants and visual-field changes in two. Controlled efficacy remains unproven.
The Body Always Collects the Bill: Why High Performers Are Researching Peptides
August 17, 2026 — Entrepreneur Sean Rakidzich rebuilt his health after workaholism and alcohol. His story reveals why peptides are attracting attention, and where evidence ends and hype begins.
Your Peptide COA Says 99% Pure. Here’s What That Actually Means
August 16, 2026 — A useful certificate of analysis answers a defined laboratory question. A purity percentage cannot answer every question about identity, quantity, contamination or suitability.
BPC-157: What “Bioregulator” Explains—and What the Evidence Shows
August 16, 2026 — A study of tendon-cell behavior can explain why a compound attracts researchers. It cannot, on its own, tell an injured person when they will recover.
Tesamorelin and Ipamorelin Are Not Interchangeable
August 15, 2026 — They are often grouped together in growth-hormone discussions. Their clinical evidence and regulatory status do not support treating them as two versions of the same recovery product.
LL-37, Wound Healing and the Limits of the Hantavirus Connection
August 15, 2026 — A human wound-healing program shows both the promise and the difficulty of translating LL-37 biology into treatment. It also shows why an immune-related mechanism cannot establish an antiviral use.